Northwick Park hospital

Harrow HA1 3UJ

6 studies enrolling now · 17 studies all time

What they study most

Cancer, Chronic Lymphocytic Leukemia, Critical Illness, Diabetes Mellitus, Diabetic Foot Ulcer, Heart Failure, Hyperkalemia, Ischemic Attack, Transient, Leukemia, Macular Edema, Malnutrition, Myelodysplastic Syndrome

Studies at this site

• A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema — Recruiting now
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart — Recruiting now
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities — Recruiting now
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) — Recruiting now
• Met Non Small Cell Cancer Registry (MOMENT) — Recruiting now
• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Recruiting now
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML — Running, not enrolling
• Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers — Completed
• A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Running, not enrolling
• HbA1c Variation Study — Completed
• Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia — Completed
• Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) — Completed
• The Effect of Higher Protein Dosing in Critically Ill Patients — Completed
• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Completed
• Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) — Stopped early
• A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) — Completed
• Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial — Stopped early